Simon R Lord

22PUBLICATIONS
127CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyTumour immunologySolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jul 14, 2026
Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

|Jun 08, 2026
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

|May 26, 2026
Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

|Mar 11, 2026
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Bruno Beernaert, Rose L Jady-Clark, Parin Shah

|Oct 10, 2025
A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.

Javier Cortés, Araceli Priego, Elena Garralda

|Mar 06, 2025
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

R C Coombes, Sacha Howell, Simon R Lord

Pageof 4

Frequent Collaborators

3 joint publications

Matthew G Krebs

3 joint publications

R C Coombes

3 joint publications

Zahi Mitri

3 joint publications

Simak Ali